Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma	Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma	Not yet recruiting	Phase 2	2026-09-10		NCT07812467

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Pfizer	431
Shanghai Zhongshan Hospital	347

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Zhongshan Hospital, Fudan University	Shanghai	China	86

Clinical trials